Hadasit Bio
HBL - Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It operates in the fields of oncology, regenerative medicine, and inflammatory disease. The company develops biological drugs; and plasma RNA biomarkers for colorectal cancer. It offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. HBL - Hadasit Bio-Holdings L… Read more
Hadasit Bio (HDST) - Total Assets
Latest total assets as of June 2023: ILA14.67 Million ILA
Based on the latest financial reports, Hadasit Bio (HDST) holds total assets worth ILA14.67 Million ILA as of June 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hadasit Bio - Total Assets Trend (2008–2022)
This chart illustrates how Hadasit Bio’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hadasit Bio - Asset Composition Analysis
Current Asset Composition (December 2022)
Hadasit Bio's total assets of ILA14.67 Million consist of 41.2% current assets and 58.8% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 2.1% |
| Accounts Receivable | ILA0.00 | 0.0% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2008–2022)
This chart illustrates how Hadasit Bio's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hadasit Bio's current assets represent 41.2% of total assets in 2022, an increase from 0.0% in 2008.
- Cash Position: Cash and equivalents constituted 2.1% of total assets in 2022, down from 34.4% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2008.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Hadasit Bio Competitors by Total Assets
Key competitors of Hadasit Bio based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Macrogen Inc
KQ:038290
|
Korea | ₩341.60 Billion |
|
Panagene Inc
KQ:046210
|
Korea | ₩101.91 Billion |
|
Cell Biotech Co. Ltd
KQ:049960
|
Korea | ₩134.57 Billion |
|
Bioneer Corporation
KQ:064550
|
Korea | ₩376.52 Billion |
|
MEDIPOST Co. Ltd
KQ:078160
|
Korea | ₩374.57 Billion |
|
Biotoxtech Co. Ltd
KQ:086040
|
Korea | ₩132.45 Billion |
|
Peptron Inc
KQ:087010
|
Korea | ₩183.74 Billion |
|
Idogen AB
ST:IDOGEN
|
Sweden | Skr5.12 Million |
Hadasit Bio - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Hadasit Bio generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Hadasit Bio is currently not profitable relative to its asset base.
Hadasit Bio - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.93 | 17.73 | 16.89 |
| Quick Ratio | 4.93 | 17.73 | 16.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA8.58 Million | ILA 18.33 Million | ILA 43.51 Million |
Hadasit Bio - Advanced Valuation Insights
This section examines the relationship between Hadasit Bio's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.52 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -41.3% |
| Total Assets | ILA38.95 Million |
| Market Capitalization | $37.28K USD |
Valuation Analysis
Below Book Valuation: The market values Hadasit Bio's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hadasit Bio's assets decreased by 41.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hadasit Bio (2008–2022)
The table below shows the annual total assets of Hadasit Bio from 2008 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | ILA38.95 Million | -41.35% |
| 2021-12-31 | ILA66.41 Million | +60.50% |
| 2020-12-31 | ILA41.38 Million | +339.65% |
| 2019-12-31 | ILA9.41 Million | -73.36% |
| 2018-12-31 | ILA35.34 Million | -48.49% |
| 2017-12-31 | ILA68.60 Million | -1.23% |
| 2016-12-31 | ILA69.46 Million | +1.23% |
| 2015-12-31 | ILA68.61 Million | +111.64% |
| 2014-12-31 | ILA32.42 Million | -6.73% |
| 2013-12-31 | ILA34.76 Million | -19.52% |
| 2012-12-31 | ILA43.19 Million | -0.94% |
| 2011-12-31 | ILA43.60 Million | -28.59% |
| 2010-12-31 | ILA61.05 Million | +9.03% |
| 2009-12-31 | ILA55.99 Million | +165.29% |
| 2008-12-31 | ILA21.11 Million | -- |